These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
400 related articles for article (PubMed ID: 12455727)
21. Cost evaluation of basiliximab treatment for renal transplant patients in Japan. Hasegawa T; Imai H; Miki S Pharmacoeconomics; 2003; 21(11):791-806. PubMed ID: 12859220 [TBL] [Abstract][Full Text] [Related]
22. The cost of kidney transplant over time. Barnieh L; Yilmaz S; McLaughlin K; Hemmelgarn BR; Klarenbach S; Manns BJ; For The Alberta Kidney Disease Network Prog Transplant; 2014 Sep; 24(3):257-62. PubMed ID: 25193726 [TBL] [Abstract][Full Text] [Related]
23. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study. Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348 [TBL] [Abstract][Full Text] [Related]
24. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Higgins R; Ramaiyan K; Dasgupta T; Kanji H; Fletcher S; Lam F; Kashi H Nephrol Dial Transplant; 2004 Feb; 19(2):444-50. PubMed ID: 14736972 [TBL] [Abstract][Full Text] [Related]
25. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347 [TBL] [Abstract][Full Text] [Related]
26. Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. Neylan JF; Sullivan EM; Steinwald B; Goss TF Am J Kidney Dis; 1998 Nov; 32(5):770-7. PubMed ID: 9820446 [TBL] [Abstract][Full Text] [Related]
27. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Hardinger KL; Bohl DL; Schnitzler MA; Lockwood M; Storch GA; Brennan DC Transplantation; 2005 Jul; 80(1):41-6. PubMed ID: 16003231 [TBL] [Abstract][Full Text] [Related]
28. The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: tacrolimus versus cyclosporine. Woodward RS; Flore MC; Machnicki G; Brennan DC Value Health; 2011 Jun; 14(4):443-9. PubMed ID: 21315636 [TBL] [Abstract][Full Text] [Related]
29. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. Briggs D; Dudley C; Pattison J; Pfeffer P; Salmela K; Rowe P; Tydén G; Transplantation; 2003 Jun; 75(12):2058-63. PubMed ID: 12829912 [TBL] [Abstract][Full Text] [Related]
30. Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. Jurewicz WA Nephrol Dial Transplant; 2003 May; 18 Suppl 1():i7-11. PubMed ID: 12738757 [TBL] [Abstract][Full Text] [Related]
32. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Shield CF; Jacobs RJ; Wyant S; Das A Am J Kidney Dis; 1996 Jun; 27(6):855-64. PubMed ID: 8651251 [TBL] [Abstract][Full Text] [Related]
33. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Greig P; Lilly L; Scudamore C; Erb S; Yoshida E; Kneteman N; Bain V; Ghent C; Marotta P; Grant D; Wall W; Tchervenkov J; Barkun J; Roy A; Marleau D; McAlister V; Peltekian K Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Margreiter R; Lancet; 2002 Mar; 359(9308):741-6. PubMed ID: 11888584 [TBL] [Abstract][Full Text] [Related]
35. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Muduma G; Odeyemi I; Pollock RF J Med Econ; 2016 Oct; 19(10):995-1002. PubMed ID: 27172118 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Krämer BK; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Ortuño J; Sester U; Kunzendorf U; Dietl KH; Bonomini V; Rigotti P; Ronco C; Tabernero JM; Rivero M; Banas B; Mühlbacher F; Arias M; Montagnino G; Nephrol Dial Transplant; 2008 Jul; 23(7):2386-92. PubMed ID: 18258740 [TBL] [Abstract][Full Text] [Related]
37. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Liu JY; Song M; Guo M; Huang F; Ma BJ; Zhu L; Xu G; Li J; You RX Am J Ther; 2016; 23(6):e1720-e1728. PubMed ID: 25569597 [TBL] [Abstract][Full Text] [Related]
38. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Kelly D; Jara P; Rodeck B; Lykavieris P; Burdelski M; Becker M; Gridelli B; Boillot O; Manzanares J; Reding R Lancet; 2004 Sep 18-24; 364(9439):1054-61. PubMed ID: 15380964 [TBL] [Abstract][Full Text] [Related]
39. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients. Cheung CY; Wong KM; Chan HW; Liu YL; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Li CS Transpl Int; 2006 Aug; 19(8):657-66. PubMed ID: 16827683 [TBL] [Abstract][Full Text] [Related]
40. Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective. Walters SJ; Whitfield M; Akehurst RL; Chilcott JB Pharmacoeconomics; 2003; 21(2):129-38. PubMed ID: 12515574 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]